- Home
- EOSE vs KNSA Comparison
EOSE vs KNSA Comparison
Compare EOSE & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOSE
- KNSA
- Stock Information
- Founded
- EOSE 2008
- KNSA 2015
- Country
- EOSE United States
- KNSA United Kingdom
- Employees
- EOSE N/A
- KNSA N/A
- Industry
- EOSE Industrial Machinery/Components
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- EOSE Miscellaneous
- KNSA Health Care
- Exchange
- EOSE Nasdaq
- KNSA Nasdaq
- Market Cap
- EOSE 1.6B
- KNSA 1.9B
- IPO Year
- EOSE N/A
- KNSA 2018
- Fundamental
- Price
- EOSE $6.32
- KNSA $33.75
- Analyst Decision
- EOSE Strong Buy
- KNSA Strong Buy
- Analyst Count
- EOSE 3
- KNSA 6
- Target Price
- EOSE $6.50
- KNSA $40.83
- AVG Volume (30 Days)
- EOSE 12.6M
- KNSA 691.9K
- Earning Date
- EOSE 07-30-2025
- KNSA 07-29-2025
- Dividend Yield
- EOSE N/A
- KNSA N/A
- EPS Growth
- EOSE N/A
- KNSA N/A
- EPS
- EOSE N/A
- KNSA 0.07
- Revenue
- EOSE $33,800,000.00
- KNSA $529,332,000.00
- Revenue This Year
- EOSE $945.82
- KNSA $37.21
- Revenue Next Year
- EOSE $195.86
- KNSA $6.10
- P/E Ratio
- EOSE N/A
- KNSA $521.23
- Revenue Growth
- EOSE 128.49
- KNSA 56.18
- 52 Week Low
- EOSE $2.06
- KNSA $17.82
- 52 Week High
- EOSE $7.36
- KNSA $34.55
- Technical
- Relative Strength Index (RSI)
- EOSE 56.22
- KNSA 65.79
- Support Level
- EOSE $5.77
- KNSA $32.90
- Resistance Level
- EOSE $6.40
- KNSA $34.55
- Average True Range (ATR)
- EOSE 0.39
- KNSA 0.96
- MACD
- EOSE -0.06
- KNSA -0.02
- Stochastic Oscillator
- EOSE 48.25
- KNSA 71.22
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.